MX2007011859A - Compuestos mejorados farmacocineticamente. - Google Patents

Compuestos mejorados farmacocineticamente.

Info

Publication number
MX2007011859A
MX2007011859A MX2007011859A MX2007011859A MX2007011859A MX 2007011859 A MX2007011859 A MX 2007011859A MX 2007011859 A MX2007011859 A MX 2007011859A MX 2007011859 A MX2007011859 A MX 2007011859A MX 2007011859 A MX2007011859 A MX 2007011859A
Authority
MX
Mexico
Prior art keywords
improved compounds
pharmacokinetically improved
pharmacokinetically
compounds
r0ck2
Prior art date
Application number
MX2007011859A
Other languages
English (en)
Inventor
Siya Ram
Paul Sweetnam
Stewart Campbell
Alessandra Bartolozzi
Hope Foudoulakis
Brian Kirk
Original Assignee
Surface Logix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Logix Inc filed Critical Surface Logix Inc
Publication of MX2007011859A publication Critical patent/MX2007011859A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Composite Materials (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invencion se relaciona con inhibidores de ROK1 y ROCK2 y con metodos para modular las propiedades farmacocineticas y/o farmacodinamicas de esos compuestos. Tambien se proporcionan metodo para inhibir ROCK1 y ROCK2 que son utiles para el tratamiento de la enfermedad.
MX2007011859A 2005-03-25 2006-03-27 Compuestos mejorados farmacocineticamente. MX2007011859A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66516505P 2005-03-25 2005-03-25
PCT/US2006/011271 WO2006105081A2 (en) 2005-03-25 2006-03-27 Pharmacokinetically improved compounds

Publications (1)

Publication Number Publication Date
MX2007011859A true MX2007011859A (es) 2008-04-04

Family

ID=37054004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007011859A MX2007011859A (es) 2005-03-25 2006-03-27 Compuestos mejorados farmacocineticamente.

Country Status (21)

Country Link
US (6) US8357693B2 (es)
EP (1) EP1865958B1 (es)
JP (2) JP2008534518A (es)
KR (1) KR20080081122A (es)
CN (1) CN101208094B (es)
AU (1) AU2006230159A1 (es)
BR (1) BRPI0622285A2 (es)
CA (1) CA2602254C (es)
CR (1) CR9465A (es)
EA (1) EA022875B1 (es)
EC (1) ECSP077836A (es)
ES (1) ES2549397T3 (es)
GE (1) GEP20105029B (es)
IL (1) IL186299A0 (es)
MX (1) MX2007011859A (es)
NO (1) NO20075145L (es)
NZ (1) NZ562083A (es)
SG (1) SG155163A1 (es)
UA (1) UA96126C2 (es)
WO (1) WO2006105081A2 (es)
ZA (1) ZA200708858B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
AU2006275514B2 (en) 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CA2649995A1 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (aeaa) compounds and their use
KR20090042863A (ko) * 2006-08-24 2009-04-30 서피스 로직스, 인크. 약물동력학적으로 향상된 화합물
CA2707449A1 (en) 2006-12-01 2009-06-12 President And Fellows Of Harvard College Compounds and methods for enzyme-mediated tumor imaging and therapy
KR101444489B1 (ko) 2007-02-01 2014-09-24 리스버로직스 코퍼레이션 심혈관 질환을 예방 및 치료하기 위한 화합물
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
US20100183604A1 (en) * 2007-06-19 2010-07-22 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
EP2346837B8 (en) 2008-06-26 2015-04-15 Resverlogix Corporation Methods of preparing quinazolinone derivatives
PL2344474T3 (pl) 2008-09-02 2016-03-31 Novartis Ag Pochodne pikolinamidu jako inhibitory kinaz
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
MX2011009568A (es) * 2009-03-09 2011-12-06 Surface Logix Inc Inhibidores de la rho cinasa.
JP5795304B2 (ja) * 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
PT2421533T (pt) 2009-04-22 2019-01-21 Resverlogix Corp Novos agentes anti-inflamatórios
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
KR20150013548A (ko) 2012-05-21 2015-02-05 노파르티스 아게 키나제 억제제로서의 신규 고리-치환된 n-피리디닐 아미드
WO2013191244A1 (ja) * 2012-06-21 2013-12-27 大正製薬株式会社 ピリドピリミジン－４－オン誘導体
HRP20220913T1 (hr) 2012-10-05 2022-10-28 Kadmon Corporation, Llc Inhibitori rho kinaze
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
HUE043465T2 (hu) 2013-08-23 2019-08-28 Neupharma Inc Kémiai anyagok, készítmények és módszerek
AU2016220219B2 (en) 2015-02-17 2020-05-14 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
EP3313449B1 (en) 2015-06-24 2020-09-23 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
AU2016361441B2 (en) * 2015-11-25 2021-08-12 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof
AU2017312561B2 (en) 2016-08-15 2022-06-30 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2018201006A1 (en) * 2017-04-28 2018-11-01 Kadmon Corporation, Llc Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors
WO2019001572A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
JP7039802B2 (ja) 2017-06-30 2022-03-23 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP3676262A4 (en) 2017-09-03 2021-03-31 Angion Biomedica Corp. VINYLHETEROCYCLENE AS RHO-ASSOCIATED COILED COIL KINASE (ROCK) INHIBITORS
DK3749669T3 (da) 2018-02-06 2023-06-06 Ideaya Biosciences Inc Ahr-modulatorer
US11345678B2 (en) 2018-04-18 2022-05-31 Medshine Discovery Inc. Benzopyrazole compound used as RHO kinase inhibitor
WO2020094111A1 (zh) * 2018-11-09 2020-05-14 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途
CN114555561B (zh) 2019-10-18 2023-08-11 南京明德新药研发有限公司 作为rho激酶抑制剂的苯并吡唑类化合物的盐型、晶型及其制备方法
WO2021129589A1 (zh) * 2019-12-27 2021-07-01 广东东阳光药业有限公司 Kd-025的新晶型及其制备方法
CA3186800A1 (en) * 2020-07-22 2022-01-27 Teva Pharmaceuticals International Gmbh Solid state forms of belumosudil and belumosudil salts
WO2022042666A1 (zh) * 2020-08-28 2022-03-03 杭州邦顺制药有限公司 选择性rock2激酶抑制剂
WO2022170864A1 (zh) * 2021-02-09 2022-08-18 苏州科睿思制药有限公司 Belumosudil甲磺酸盐的晶型及其制备方法和用途
CN114573566B (zh) * 2021-03-04 2023-05-30 杭州邦顺制药有限公司 选择性rock2激酶抑制剂
WO2023285706A1 (en) 2021-07-16 2023-01-19 Sandoz Ag Solid-state forms of 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl )phenoxy)-n- isopropylacetamide methane sulfonic acid salt
WO2023205153A1 (en) 2022-04-19 2023-10-26 Kadmon Corporation, Llc Belumosudil for treating chronic lung allograft dysfunction
WO2024000060A1 (en) * 2022-06-30 2024-01-04 Apotex Inc Salts of belumosudil, crystalline forms and pharmaceutical compositions thereof and their use in the treatment of chronic graft-versus-host disease
CA3178086A1 (en) 2022-07-14 2024-01-14 Kadmon Corporation, Llc Methods of administering belumosudil for treatment of chronic graft versus host disease in patient subpopulations
CA3178096A1 (en) 2022-07-14 2024-01-14 Kadmon Corporation, Llc Methods of administering belumosudil for treatment of chronic graft versus host disease
WO2024015066A1 (en) 2022-07-14 2024-01-18 Kadmon Corporation, Llc Methods of administering belumosudil in combination with cyp3a inducers and/or proton pump inhibitors
WO2024015068A1 (en) 2022-07-14 2024-01-18 Kadmon Corporation, Llc Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease
CN115385899B (zh) * 2022-09-08 2024-04-02 药康众拓(江苏)医药科技有限公司 ROCK2抑制剂belumosudil的氘代药物及用途
WO2024063770A1 (en) 2022-09-21 2024-03-28 Kadmon Corporation, Llc Liquid formulation of belumosudil
WO2024100601A1 (en) 2022-11-11 2024-05-16 Assia Chemical Industries Ltd. Solid state forms of belumosudil and processes for preparation thereof
WO2024118556A1 (en) 2022-11-29 2024-06-06 Kadmon Corporation, Llc Solid dispersion comprising amorphous 2-[3-[4-(lh-indazol-5- ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-yl-acetamide
WO2024124084A1 (en) 2022-12-09 2024-06-13 Kadmon Corporation, Llc Methods of administering belumosudil for treatment of multiple myeloma

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9800215A (es) * 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
CN100389828C (zh) 1996-08-12 2008-05-28 三菱制药株式会社 含Rho激酶抑制剂的药物制剂
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
EP1270570B1 (en) * 2000-03-16 2006-05-31 Mitsubishi Pharma Corporation Amide compounds and use thereof
WO2001070746A1 (fr) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Derives de furoisoquinoleine, leur procede de production et leur utilisation
US6699665B1 (en) 2000-11-08 2004-03-02 Surface Logix, Inc. Multiple array system for integrating bioarrays
PE20020958A1 (es) * 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
AU2002250394A1 (en) 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
WO2003012392A2 (en) 2001-07-27 2003-02-13 Surface Logix, Inc. Resealable and sealable devices for biochemical assays
JP2005509737A (ja) 2001-08-27 2005-04-14 サーフェイス ロジックス，インコーポレイティド 単層で被覆された表面への生物学的分子の不動化
JP2003221386A (ja) * 2001-11-26 2003-08-05 Takeda Chem Ind Ltd 二環性誘導体、その製造法およびその用途
DE10162435A1 (de) 2001-12-19 2003-07-17 Joerg Lahann Verfahren zur Erzeugung von Oberflächenbeschichtungen, die die Adsorption von Proteinen bzw. die Adhäsion von Bakterien und/oder Zellen vermindern
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
EP1567528A1 (en) * 2002-11-21 2005-08-31 Eli Lilly And Company Mixed lineage kinase modulators
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
US20040266755A1 (en) * 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
US20070275961A1 (en) * 2003-06-04 2007-11-29 Vernalis (Cambridge) Limited. Triazolo ' 1, 5-A ! Pyrimidines and Their Use in Medicine
CA2536954C (en) * 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
RU2405784C2 (ru) * 2003-10-15 2010-12-10 Оси Фармасьютикалз, Инк. Имидазопиразины в качестве ингибиторов тирозинкиназ
KR20080015391A (ko) * 2005-02-18 2008-02-19 서피스 로직스, 인크. 작용성 잔기 또는 기를 포함하는 약력학적으로 개선된화합물의 제조 방법 및 상기 화합물을 포함하는 약학조성물
CN102351862A (zh) * 2005-02-18 2012-02-15 表面线段公司 药动学改善的化合物
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
KR20090042863A (ko) * 2006-08-24 2009-04-30 서피스 로직스, 인크. 약물동력학적으로 향상된 화합물

Also Published As

Publication number Publication date
WO2006105081A3 (en) 2007-05-10
SG155163A1 (en) 2009-09-30
ZA200708858B (en) 2009-09-30
EP1865958A4 (en) 2012-01-25
US9440961B2 (en) 2016-09-13
US20150344464A1 (en) 2015-12-03
AU2006230159A1 (en) 2006-10-05
US20100144707A1 (en) 2010-06-10
US10570123B2 (en) 2020-02-25
GEP20105029B (en) 2010-06-25
UA96126C2 (ru) 2011-10-10
NO20075145L (no) 2007-11-28
EP1865958A2 (en) 2007-12-19
ECSP077836A (es) 2008-01-23
WO2006105081A2 (en) 2006-10-05
US20190177311A1 (en) 2019-06-13
BRPI0622285A2 (pt) 2011-08-16
JP2015193639A (ja) 2015-11-05
US8916576B2 (en) 2014-12-23
CN101208094B (zh) 2014-10-15
JP2008534518A (ja) 2008-08-28
CA2602254C (en) 2015-03-24
KR20080081122A (ko) 2008-09-08
JP5956661B2 (ja) 2016-07-27
EA200702048A1 (ru) 2008-04-28
US20210017166A1 (en) 2021-01-21
EA022875B1 (ru) 2016-03-31
CN101208094A (zh) 2008-06-25
US20180072710A1 (en) 2018-03-15
CA2602254A1 (en) 2006-10-05
IL186299A0 (en) 2008-01-20
CR9465A (es) 2008-06-19
US8357693B2 (en) 2013-01-22
NZ562083A (en) 2010-12-24
EP1865958B1 (en) 2015-07-08
ES2549397T3 (es) 2015-10-27
US20130131047A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
MX2007011859A (es) Compuestos mejorados farmacocineticamente.
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
TW200640924A (en) VEGF-R2 inhibitors and methods
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
WO2008054599A3 (en) Rho kinase inhibitors
MX2011009568A (es) Inhibidores de la rho cinasa.
TW200801008A (en) Protein kinase inhibitors
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
PH12013502230A1 (en) Multispecific antibodies
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
TW200716624A (en) Compounds for modulating TRPV3 function
EA200970738A1 (ru) Ингибиторы активности akt
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MX2012003311A (es) Inhibidores de miristato de moleculas pequeñas contra bcr-abl y metodos de uso.
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
EA201070256A1 (ru) Способ и промежуточные соединения для получения ингибиторов интегразы
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
UA85505C2 (en) Kinase inhibitors
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
TW200724140A (en) Hydantoin compounds
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal